TransCode Therapeutics Inc. (NASDAQ:RNAZ) Sees Large Decline in Short Interest

TransCode Therapeutics Inc. (NASDAQ:RNAZ) was the target of a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 34,446 shares, a decrease of 34.8% from the June 30th total of 52,823 shares. Based on an average daily trading volume, of 41,287 shares, the short-interest ratio is presently 0.8 days. Approximately 3.3% of the shares of the company are short sold.

TransCode Therapeutics Price Performance

Shares of RNAZ opened at $4.56 on Friday. The stock has a fifty day moving average price of $6.31 and a 200 day moving average price of $7.99. The company has a market cap of $4.83 million, a P/E ratio of -0.09 and a beta of 1.23. TransCode Therapeutics has a 12 month low of $3.82 and a 12 month high of $20.99.

TransCode Therapeutics (NASDAQ:RNAZ) last announced its quarterly earnings results on Friday, May 15th. The company reported ($21.28) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.